| Literature DB >> 29969320 |
Philipp Schuetz1,2, Rebekka Bolliger2, Meret Merker2, Mirjam Christ-Crain1,3, Daiana Stolz1,4, Michael Tamm1,4, Charles E Luyt5, Michel Wolff6, Stefan Schroeder7, Vandack Nobre8, Konrad Reinhart9, Angela Branche10, Pierre Damas11, Maarten Nijsten12, Rodrigo O Deliberato13, Alessia Verduri14, Bianca Beghé14, Bin Cao15, Yahya Shehabi16,17, Jens-Ulrik S Jensen18,19, Albertus Beishuizen20, Evelien de Jong21, Matthias Briel1,22, Tobias Welte23, Beat Mueller1,2.
Abstract
INTRODUCTION: Although evidence indicates that use of procalcitonin to guide antibiotic decisions for the treatment of acute respiratory infections (ARI) decreases antibiotic consumption and improves clinical outcomes, algorithms used within studies had differences in PCT cut-off points and frequency of testing. We therefore analyzed studies evaluating procalcitonin-guided antibiotic therapy and propose consensus algorithms for different respiratory infection types. Areas covered: We systematically searched randomized-controlled trials (search strategy updated on February 2018) on procalcitonin-guided antibiotic therapy of ARI in adults using a pre-specified Cochrane protocol and analyzed algorithms from 32 trials that included 10,285 patients treated in primary care settings, emergency departments (ED), and intensive care units (ICU). We derived consensus algorithms for use of procalcitonin by the type of ARI including community-acquired pneumonia, bronchitis, chronic obstructive pulmonary disease or asthma exacerbation, sepsis, and post-operative sepsis due to respiratory infection. Consensus algorithm recommendations differ with regard to timing of treatment (i.e. timing of initiation in low-risk patients or discontinuation in high-risk patients) and procalcitonin cut-off points for the recommendation/strong recommendation to discontinue antibiotics (≤ 0.25/≤ 0.1 µg/L in ED and inpatients, ≤ 0.5/≤ 0.25 µg/L in ICU patients, and reduction by ≥ 80% from peak levels in sepsis patients). Expert commentary: Our proposed algorithms may facilitate safe and efficient implementation of procalcitonin-guided antibiotic protocols in diverse healthcare settings. Still, the decision about initiation and cessation of antibiotic treatment remains a clinical decision based on the patient assessment and the severity of illness and use of procalcitonin should not delay empirical treatment in high risk situations.Entities:
Keywords: Procalcitonin; antibiotic stewardship; pneumonia; respiratory infection; systematic review
Mesh:
Substances:
Year: 2018 PMID: 29969320 DOI: 10.1080/14787210.2018.1496331
Source DB: PubMed Journal: Expert Rev Anti Infect Ther ISSN: 1478-7210 Impact factor: 5.091